News

Novo Nordisk: The Market Has Lost Its Mind
While Novo Nordisk has gotten a lot of attention for its obesity/weight-loss drug Wegovy in recent years, Novo Nordisk is ...
Novo Nordisk CEO warns of layoffs as Wegovy challenge heats up
Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...
Ozempic Maker Novo Nordisk Terminates Multiple Pipeline Programs, Faces Investor Lawsuit Over GLP-1 Market Misrepresentation
Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...
Novo Nordisk: More Pain On The Horizon
Novo Nordisk faces slowing revenue growth, weak Q2 2025 results, and a more conservative outlook. Read why I rate NVO stock a ...
Novo Nordisk, TSMC, Glencore: Stocks Around the World in Focus
The pharmaceutical company's quarterly sales of its blockbuster Wegovy drug surged by two-thirds, despite many Americans ...
Cash pay is 'going to constitute a major part of the Wegovy business': Novo Nordisk CFO
Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...
Watch These Novo Nordisk Stock Price Levels After Last Week's 33% Drop
Novo Nordisk's U.S.-listed shares shed a third of their value last week after the company cut its full-year outlook and named ...
Novo Nordisk AS (NVO) Q2 2025 Earnings Call Highlights: Robust Growth in Obesity Care and ...
Novo Nordisk AS (NVO) reports significant sales and profit growth, driven by obesity care expansion and strategic ...